Xinlitai announced that due to the repurchase clause of the original agreement, the company plans to repurchase part of the shares of Xintai Medical's holding subsidiary: transfer 7.0863.21 million shares of Xintai Medical held by Xinshi Xinxing, with a transfer price of 426 million yuan; transfer 121.68 million shares of Xintai Medical held by Xinshi Xinjie, with a transfer price of 7063 million yuan. After the repurchase is completed, the company's shareholding ratio of Xintai Medical will rise from 87.3639% to 93.5063%. Xintai Medical is still a holding subsidiary within the scope of the company's consolidated statements. The repurchase capital is self-funded by the company and will not affect production, operation and funding arrangements.

Xinlitai announced that due to the repurchase clause of the original agreement, the company plans to repurchase part of the shares of Xintai Medical's holding subsidiary: transfer 7.0863.21 million shares of Xintai Medical held by Xinshi Xinxing, with a transfer price of 426 million yuan; transfer 121.68 million shares of Xintai Medical held by Xinshi Xinjie, with a transfer price of 7063 million yuan. After the repurchase is completed, the company's shareholding ratio of Xintai Medical will rise from 87.3639% to 93.5063%. Xintai Medical is still a holding subsidiary within the scope of the company's consolidated statements. The repurchase capital is self-funded by the company and will not affect production, operation and funding arrangements.